Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Case report

Blood transcript analysis and metastatic recurrent small bowel carcinoid management

Authors: Irvin M Modlin, Ignat Drozdov, Lisa Bodei, Mark Kidd

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Detection of neuroendocrine tumor (NET) disease progression is a key issue in determining management. Currently, assessment is by imaging (MRI/CT and Octreoscan®) and plasma Chromogranin A (CgA) measurement.

Case presentation

We report use of a NET-specific multigene PCR-derived blood transcript signature (NET Index) to assess disease and correlated CgA and gene transcripts with MRI, CT, Octreoscan®, 11C-5HTP-PET/CT and 68Ga-DOTA-PET/CT in a patient with NET.

Conclusions

Our results identify limitations in evaluating disease status by CgA and identify that a PCR-based test is more sensitive. Alteration in NET blood gene transcript levels prior to image-based tumor confirmation suggests this parameter may also have utility as an index of therapeutic efficacy.
Appendix
Available only for authorised users
Literature
1.
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008, 9: 61-72.CrossRefPubMed
2.
Giandomenico V, Modlin IM, Pontén F, Nilsson M, Landegren U, Bergqvist J, Khan MS, Millar RP, Långström B, Borlak J, Eriksson B, Nielsen B, Baltzer L, Waterton JC, Ahlström H, Öberg K: Improving the diagnosis and management of neuroendocrine tumors: utilizing new advances in biomarker and molecular imaging science. Neuroendocrinology. 2013, 28: 28-
3.
Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM: The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011, 40: 111-134. viii. doi:10.1016/j.ecl.2010.12.001CrossRefPubMed
4.
Modlin I, Drozdov I, Kidd M: The Identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS One. 2013, 8: e63364-CrossRefPubMedPubMedCentral
5.
Modlin IM, Gustafsson BI, Drozdov I, Nadler B, Pfragner R, Kidd M: Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors. Ann Surg Oncol. 2009, 16: 487-498.CrossRefPubMed
6.
Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE: The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010, 252: 850-856.CrossRefPubMed
7.
Elias D, Lefevre JH, Duvillard P, Goéré D, Dromain C, Dumont F, Baudin E: Hepatic metastases from neuroendocrine tumors with a “thin slice” pathological examination: they are many more than you think. Ann Surg. 2010, 251: 307-310. doi:10.1097/SLA.0b013e3181bdf8cfCrossRefPubMed
8.
Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, Binderup T, Rasmussen P, Elema D, Klausen TL, Holm S, von Benzon E, Højgaard L, Kjaer A: Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med. 2012, 53: 1207-1215. doi:10.2967/jnumed.111.101469. Epub 2012 Jul 10CrossRefPubMed
9.
Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E: Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008, 100: 1282-1289. Epub 2008 Sep 9CrossRefPubMedPubMedCentral
10.
Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC: Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011, 29: 934-943.CrossRefPubMedPubMedCentral
11.
Frilling A, Akerstrom G, Falconi M, Pavel M, Ramos J, Kidd M, Modlin IM: Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer. 2012, 19: R163-R185. doi:10.1530/ERC-12-0024. Print 2012 OctCrossRefPubMed
12.
Schreiter NF, Brenner W, Nogami M, Buchert R, Huppertz A, Pape UF, Prasad V, Hamm B, Maurer MH: Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012, 39: 72-82. doi:10.1007/s00259-011-1935-5. Epub 2011 Sep 17CrossRefPubMed
13.
Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, Pavel M, Stelter L, Kropf S, Wiedenmann B, Amthauer H: Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology. 2010, 91: 101-109. Epub 2009 Dec 9CrossRefPubMed
14.
Bodei L, Kidd M, Modlin I, Paganelli G: Nuclear medicine in the diagnosis and therapy of neuroendocrine tumors. Nuclear Oncology. Edited by: Akotlun C, Goldsmith S. 2014, Wolters Kluwer Health
15.
Thomas D, Tsolakis AV, Grozinsky-Glasberg S, Fraenkel M, Alexandraki K, Sougioultzis S, Gross DJ, Kaltsas G: Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol. 2013, 168: 185-193. doi:10.1530/EJE-12-0836. Print 2013 FebCrossRefPubMed
16.
De Herder WW: Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007, 21: 33-41.CrossRefPubMed
17.
Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, Scherag A, Hahmann M, Müller HH, Barth P: Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol. 2008, 6: 820-827. Epub 2008 Jun 10CrossRefPubMed
18.
Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E, Bombardieri E: Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999, 86: 858-865.CrossRefPubMed
19.
Jensen EH, Kvols L, McLoughlin JM, Lewis JM, Alvarado MD, Yeatman T, Malafa M, Shibata D: Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol. 2007, 14: 780-785. Epub 2006 Dec 5CrossRefPubMed
20.
Sondenaa K, Sen J, Heinle F, Fjetland L, Gudlaugsson E, Syversen U: Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report. World J Surg. 2004, 28: 890-895.CrossRefPubMed
21.
Marotta V, Nuzzo V, Ferrara T, Zuccoli A, Masone M, Nocerino L, Del Prete M, Marciello F, Ramundo V, Lombardi G, Vitale M, Colao A, Faggiano A: Limitations of Chromogranin A in clinical practice. Biomarkers. 2012, 17: 186-191. doi:10.3109/1354750X.2012.654511. Epub 2012 Feb 6CrossRefPubMed
22.
Zuetenhorst JM, Korse CM, Bonfrer JM, Peter E, Lamers CB, Taal BG: Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors. Clin Chem. 2004, 50: 1634-1639. Epub 2004 Jul 9CrossRefPubMed
23.
Allen KR, Degg TJ, Anthoney DA, Fitzroy-Smith D: Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examples. Ann Clin Biochem. 2007, 44: 300-307.CrossRefPubMed
24.
Modlin I, Drozdov I, Alaimo D, Callahan S, Teixiera N, Bodei L, Kidd M: A multianalyte PCR blood test outperforms single analyte ELISAs for neuroendocrine tumor detection. Endocr Relat Cancer. 2014, 21: 615-28.CrossRefPubMed
25.
Modlin I, Drozdov I, Kidd M: A multitranscript blood neuroendocrine tumor molecular signature to identify treatment efficacy and disease progress. J Clin Oncol. 2013, 31 (Suppl): A4137-
26.
Stokkel MP, Rietbergen DD, Korse CM, Taal BG: Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors. Nucl Med Commun. 2011, 32: 731-737.CrossRefPubMed
Metadata
Title
Blood transcript analysis and metastatic recurrent small bowel carcinoid management
Authors
Irvin M Modlin
Ignat Drozdov
Lisa Bodei
Mark Kidd
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-564

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway

Research article

Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study

Research article

Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma

Research article

High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients

Research article

FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling

Research article

Serum soluble ST2 is associated with ER-positive breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits